Abstract
Dengue is a major mosquito-borne viral disease whose rapid progression from self-limiting fever to hemorrhagic or shock syndrome (DHF/DSS) remains difficult to predict using conventional clinical markers. Metabolomics offers a promising avenue for identifying non-invasive biomarkers of infection and severity, but the evidence remains scattered across biofluids and analytical platforms. This systematic review synthesized human metabolomic studies of dengue infection to characterize the biofluids, techniques, and metabolic signatures reported to date. Following PRISMA 2020 guidelines, PubMed, ScienceDirect, and Web of Science were searched for studies applying NMR- or MS-based metabolomics to human dengue samples, screened against PECO criteria requiring a healthy-control or severity comparison group. Of 780 records identified, 17 studies met all eligibility criteria. Most studies (14/17) analyzed blood-derived matrices (serum, plasma, or whole blood), while three analyzed urine; no eligible study examined feces, saliva, tears, sweat, or cerebrospinal fluid. Across studies, three convergent patterns emerged with increasing disease severity: depletion of serotonin and related tryptophan-pathway metabolites, disturbance of glycerophospholipid and lysophospholipid classes, and elevation of markers of hepatic and lipid-metabolic stress (bile acids, VLDL/LDL changes, acylcarnitines). Serotonin combined with IFN-γ achieved the strongest discriminatory performance reported (AUC = 0.92) for progression to DHF, while urinary alkanes and betaine emerged as candidate non-invasive markers linked to infection status and comorbidities such as diabetes. These findings highlight a persistent reliance on blood-based sampling and a near-total absence of studies exploring alternative, more accessible biofluids, representing a clear gap for future non-invasive biomarker research in dengue.

This publication has 21 references indexed in Scilit: